Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.

Nature communications - 6 Jan 2017

Zhou Jin, Wu Zhong, Wong Gabrielle, Pectasides Eirini, Nagaraja Ankur, Stachler Matthew, Zhang Haikuo, Chen Ting, Zhang Haisheng, Liu Jie Bin, Xu Xinsen, Sicinska Ewa, Sanchez-Vega Francisco, Rustgi Anil K, Diehl J Alan, Wong Kwok-Kin, Bass Adam J

Abstract excerpt

Oesophageal squamous cell carcinoma is a deadly disease where systemic therapy has relied upon empiric chemotherapy despite the presence of genomic alterations pointing to candidate therapeutic targets, including recurrent amplification of the gene encoding receptor tyrosine kinase epidermal growth factor receptor (EGFR). Here, we demonstrate that EGFR-targeting small-molecule inhibitors have efficacy in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclin-Dependent Kinase 4
Share to Cyclin-Dependent Kinase 6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epithelial-Mesenchymal Transition

Share to Erlotinib Hydrochloride

Share to Esophageal Neoplasms

Share to Esophageal Squamous Cell Carcinoma

Share to Mitogen-Activated Protein Kinases

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 28059068
DOI: 10.1038/ncomms13897
PMCID: PMC5227099

Genes

EGFR
CDK4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.PMID 28059068Read ↗

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.Semantic proximity Read ↗

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.Semantic proximity Read ↗

CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability to cause EGFR targeted therapy resistance in lung cancerSemantic proximity Read ↗

Targeting the ERK/MAPK Pathway in Cancer: Oncogenic Mechanisms, Therapeutic Resistance, and Emerging Gene-Based StrategiesSemantic proximity Read ↗

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant CancersSemantic proximity Read ↗

New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors.Semantic proximity Read ↗

Mechanism of EGER-related cancer drug resistance.Semantic proximity Read ↗

New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune CheckpointsSemantic proximity Read ↗

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancerSemantic proximity Read ↗

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in <i>KRAS</i> -Mutant CancersSemantic proximity Read ↗

Dual cyclin‐dependent kinase 4/6 inhibition by PD‐0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cellsSemantic proximity Read ↗

EGFR Mutations in Head and Neck Squamous Cell Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.